Cell membrane lipid phosphatidylserine (PS) is abnormally exposed on the surface of cancer cells, allowing tumour cells to evade the normal immune response. This SME is developing molecules that bind to PS as a targeting technology for delivery of drug conjugates to cancer cells. The SME is currently seeking:
– PS Biology expertise, via a strategic research collaboration or consultancy
– Strategic collaboration with drug developers
– Investment to develop the project to clinical trial readiness.
